![](/img/cover-not-exists.png)
Y 90 -Ibritumomab tiuxetan (Y 90 -IT) and high-dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to chemotherapy: a feasibility trial (SAKK 37/05)
Voegeli, Michèle, Rondeau, Stephanie, Berardi Vilei, Simona, Lerch, Erika, Wannesson, Luciano, Pabst, Thomas, Rentschler, Jochen, Bargetzi, Mario, Jost, Lorenz, Ketterer, Nicolas, Bischof Delaloye, AnYear:
2016
Language:
english
Journal:
Hematological Oncology
DOI:
10.1002/hon.2348
File:
PDF, 630 KB
english, 2016